Product category:
Microplates/microarrays and readers
News Release from: Oxford Gene Technology
Edited by the Laboratorytalk Editorial
Team on 11 January 2007
OGT grants Tridend option to Masstag
Oxford Gene Technology has agreed to grant an exclusive option to licence the technology developed by its former Tridend business unit to MassTag Technologies
MassTag Technologies is a biotechnology company developing molecular tools for the research and biotechnology market The option will convert to an exclusive licence subject to MassTag successfully concluding its current capital raising
This article was originally published on Laboratorytalk on 12 Sep 2006 at 8.00am (UK)
Related stories
OGT extends its Chip2 microarray family
Oxford Gene Technology (OGT) has extended its Chip2 family of ChIP on chip microarray products with the addition of four prokaryote species
Under the terms of the licence, OGT will become a minority shareholder in MassTag.
Mike Evans, CEO at OGT said: "Following a strategic review, OGT decided to focus its efforts in the field of microarrays and sought partners capable of maximising the value from the Tridend business unit products and intellectual property.
"We are pleased to announce that we have found a partner who, we believe, has the right qualities and expertise to successfully exploit the products".
John Thornback, CEO and co-founder of MassTag stated: "We are excited by the wide range of possible applications of the Tridend technology.
"The extensive intellectual property package opens up a large number of different product lines and markets.
"As we are focused on the research and non clinical markets we can bring these products to market quickly and cost effectively.".
• Oxford Gene Technology: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
